We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros Protein Technologies Introduces Next Generation Gyrolab Protein A Kit for Biotherapeutics
Product News

Gyros Protein Technologies Introduces Next Generation Gyrolab Protein A Kit for Biotherapeutics

Gyros Protein Technologies Introduces Next Generation Gyrolab Protein A Kit for Biotherapeutics
Product News

Gyros Protein Technologies Introduces Next Generation Gyrolab Protein A Kit for Biotherapeutics

Credit: Gyros Protein Technologies

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Gyros Protein Technologies Introduces Next Generation Gyrolab Protein A Kit for Biotherapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gyros Protein Technologies has announced it has launched a new version of its Gyrolab™ Protein A Kit.


The new Protein A Kit offers increased efficiency and throughput for quantification of residual Protein A ligands, with 96 microstructures, this next generation in Protein A detection and quantification offers double the capacity of the previous Gyrolab Mixing CD. Two ready to use versions of the kit – Native Protein A and MabSelect™ Sure – are designed for use with Gyrolab systems, and include an enhanced protocol for automated acid pretreatment of harvested samples from downstream purification of biotherapeutics.


Determination of residual protein A is an essential regulatory requirement for the safety evaluation of biotherapeutics. During the purification of biotherapeutics, Protein A can leach from the chromatography support and co-elute with the therapeutic antibody product. If bound to immunoglobulins, Protein A can increase the risk of adverse reactions. 


Mattias Bylund, Product Manager, Gyros Protein Technologies, said: “We are pleased to offer our customers this improved version of our Protein A Kit, enabling them to easily and quickly quantify residual Protein A ligands in the presence of high IgG concentrations. The launch of the new kits forms part of Gyros Protein Technologies’ commitment to developing immunoassay solutions for the bioprocess market.”

Advertisement